There’s a saying in Brussels called going ‘into the tunnel’. It’s when negotiators get together to try to plot a path to resolving Brexit. As the political turmoil continues, one certainty is that pharmaceutical innovators have been meticulously planning for Brexit. For two years or more, they have been reorganising supply chains and revising regulatory approvals. This work is critical in minimising the risk of disruption to the supply of medicines to patients after March 29th.
Two-thirds of people feel it is ‘unacceptable’ that life-changing medicines are available to patients in other countries before our own can get them, according to a survey conducted by Ipsos MRBI on behalf of Irish Pharmaceutical Healthcare Association (IPHA), the organisation that represents pharmaceutical innovators in Ireland.
As we near the end of the year, it’s a good time to look back on just some of the highlights of our public communications and advocacy.
With less than four months to Brexit Day, 29th March 2019, the pharmaceutical industry continues to require clarity and advice on its impact on Ireland, both from a practical and political perspective.
Professor Ian Greer, the new Vice Chancellor of Queen’s University Belfast gave an inspirational Annual Lecture of the Association of the British Pharmaceutical Industry at Stormont Buildings on 20th November.
Patients in Ireland are waiting more than twice as long as patients in other western European countries for access to many vital new medicines, figures from the Irish Pharmaceutical Healthcare Association (IPHA) have revealed.